EA202192263A1 - Замещенные бициклические соединения в качестве регуляторов фарнезоидного х-рецептора - Google Patents

Замещенные бициклические соединения в качестве регуляторов фарнезоидного х-рецептора

Info

Publication number
EA202192263A1
EA202192263A1 EA202192263A EA202192263A EA202192263A1 EA 202192263 A1 EA202192263 A1 EA 202192263A1 EA 202192263 A EA202192263 A EA 202192263A EA 202192263 A EA202192263 A EA 202192263A EA 202192263 A1 EA202192263 A1 EA 202192263A1
Authority
EA
Eurasian Patent Office
Prior art keywords
farnesoid
compounds
substituted bicyclic
bicyclic compounds
fxr
Prior art date
Application number
EA202192263A
Other languages
English (en)
Inventor
Дин А. Уокер
Сушил Джетхананд Нара
Сринивас Черуку
Кандхасами Саркунам
Фироз Али Джайпури
Ришикеш Нарайян
Субба Редди Бандредди
Сринивас Джоги
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA202192263A1 publication Critical patent/EA202192263A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Раскрыты соединения формулы (I)или их стереоизомер, таутомер, или соль, или сольват, где Q представляет собой C2-6алкенил или C2-6алкинил, каждый замещенный R1 в количестве от 0 до 2; и значения других переменных определены в настоящем документе. Указанные соединения модулируют активность фарнезоидного Х-рецептора (FXR), например, в качестве агонистов. Также раскрыты фармацевтические композиции, содержащие указанные соединения, и способы лечения заболевания, нарушения или состояния, связанного с нарушенной регуляцией FXR, такого как патологический фиброз, отторжение трансплантата, злокачественная опухоль, остеопороз и воспалительные нарушения, посредством применения соединения и фармацевтических композиций.
EA202192263A 2019-02-15 2020-02-14 Замещенные бициклические соединения в качестве регуляторов фарнезоидного х-рецептора EA202192263A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962806402P 2019-02-15 2019-02-15
PCT/US2020/018210 WO2020168148A1 (en) 2019-02-15 2020-02-14 Substituted bicyclic compounds as farnesoid x receptor modulators

Publications (1)

Publication Number Publication Date
EA202192263A1 true EA202192263A1 (ru) 2022-01-27

Family

ID=69811924

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202192263A EA202192263A1 (ru) 2019-02-15 2020-02-14 Замещенные бициклические соединения в качестве регуляторов фарнезоидного х-рецептора

Country Status (7)

Country Link
AU (1) AU2020221370A1 (ru)
BR (1) BR112021015963A2 (ru)
CA (1) CA3129533A1 (ru)
EA (1) EA202192263A1 (ru)
MX (1) MX2021009570A (ru)
SG (1) SG11202108796YA (ru)
WO (1) WO2020168148A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114945361A (zh) 2020-01-15 2022-08-26 法国国家卫生及研究医学协会 Fxr激动剂在治疗丁型肝炎病毒感染中的用途
EP4277622A1 (en) 2021-01-14 2023-11-22 ENYO Pharma Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
CN115340536A (zh) * 2021-05-13 2022-11-15 华东理工大学 含1,2,4-恶二唑的酰胺类化合物及其盐、制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1480957A1 (en) 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
WO2004032882A2 (en) 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2008011130A2 (en) 2006-07-21 2008-01-24 Takeda Pharmaceutical Company Limited Amide compounds
EP2917203B1 (en) 2012-11-02 2019-04-03 Dana-Farber Cancer Institute, Inc. Method for identifying myc inhibitors
ES2770693T3 (es) 2014-06-19 2020-07-02 Bristol Myers Squibb Co Derivados de imidazopiridazina como inhibidores de caseína quinasa 1 delta/épsilon
WO2016039734A1 (en) 2014-09-10 2016-03-17 Halliburton Energy Services, Inc. Perforating gun with integrated retaining system
EP3596053B1 (en) * 2017-03-15 2023-08-16 Organovo, Inc. Farnesoid x receptor agonists and uses thereof
SG11201908330PA (en) * 2017-03-15 2019-10-30 Metacrine Inc Farnesoid x receptor agonists and uses thereof

Also Published As

Publication number Publication date
CA3129533A1 (en) 2020-08-20
AU2020221370A1 (en) 2021-10-07
MX2021009570A (es) 2021-09-08
WO2020168148A1 (en) 2020-08-20
SG11202108796YA (en) 2021-09-29
BR112021015963A2 (pt) 2021-10-05

Similar Documents

Publication Publication Date Title
EA202192263A1 (ru) Замещенные бициклические соединения в качестве регуляторов фарнезоидного х-рецептора
EA202091063A1 (ru) Мостиковые бициклические соединения в качестве модуляторов фарнезоидного х-рецептора
MX2021009694A (es) Compuestos biciclicos sustituidos como moduladores del receptor farnesoide x.
MA49235B1 (fr) Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
EA202091101A1 (ru) Спироциклические соединения в качестве модуляторов фарнезоидного x-рецептора
EA202091084A1 (ru) Алкеновые спироциклические соединения как модуляторы фарнезоидных x-рецепторов
EA201991127A1 (ru) ЦИКЛОБУТАН- И АЗЕТИДИНСОДЕРЖАЩИЕ МОНО- И СПИРОЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV
EA202193338A1 (ru) Терапевтические композиции, включающие дейтерированные или частично дейтерированные соединения n,n-диметилтриптамина
EA202092896A1 (ru) Гетероциклические и гетероарильные соединения для лечения болезни гентингтона
MA49952B1 (fr) Dérivés de 3-(1-oxoisoindolin-2-yl)pipéridine-2,6-dione et leurs utilisations
EA201991122A1 (ru) 3-ЗАМЕЩЕННЫЕ ПРОПАНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
MX2019005243A (es) Derivados de indazol como antagonistas de integrina alfa v.
EA201991121A1 (ru) АЗОЛАМИДЫ И АЗОЛАМИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV
MX2021003706A (es) Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida.
EA201991124A1 (ru) ПИРРОЛЬНЫЕ АМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНОВ αV
MX2020012827A (es) Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes.
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
MX2022007105A (es) Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico.
PE20221460A1 (es) Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de cftr deficiente
MX2022008626A (es) Triazinonas sustituidas como agonistas del receptor de la hormona tiroidea.
EA202190272A1 (ru) Дополнительно замещенные производные триазолохиноксалина
MA41633B1 (fr) Composés amide en tant qu'agonistes du récepteur 5-ht4
MA33166B1 (fr) Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose
EA202192275A1 (ru) Замещенные амидные соединения, полезные в качестве модуляторов фарнезоидного x-рецептора